Barbara A de Weijer Selected Research

3- iodo- 2- hydroxy- 6- methoxy- N- ((1- ethyl- 2- pyrrolidinyl)methyl)benzamide

12/2011

Lower striatal dopamine D2/3 receptor availability in obese compared with non-obese subjects.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Barbara A de Weijer Research Topics

Disease

4	Insulin Resistance 01/2020 - 05/2014
3	Obesity 01/2020 - 12/2011
2	Body Weight (Weight, Body) 02/2017 - 01/2016
1	Inflammation (Inflammations) 01/2020
1	Heart Failure 02/2017
1	Weight Loss (Weight Reduction) 01/2016

Drug/Important Bio-Agent (IBA)

2	Insulin (Novolin)FDA Link 01/2020 - 01/2015
2	Glucose (Dextrose)FDA LinkGeneric 01/2020 - 01/2015
1	Messenger RNA (mRNA)IBA 01/2020
1	Vitamin A (Retinol)FDA LinkGeneric 01/2020
1	CytokinesIBA 01/2020
1	GhrelinIBA 01/2016
1	Dopamine (Intropin)FDA LinkGeneric 01/2016
1	LeptinIBA 01/2016
1	Nonesterified Fatty Acids (NEFA)IBA 01/2015
1	Dopamine Receptors (Dopamine Receptor)IBA 05/2014
1	3- iodo- 2- hydroxy- 6- methoxy- N- ((1- ethyl- 2- pyrrolidinyl)methyl)benzamideIBA 12/2011

Therapy/Procedure

2	Gastric Bypass (Roux-en-Y Gastric Bypass) 02/2017 - 05/2014
1	Bariatric Surgery 01/2016